Latest news with #TheChristHospital
Yahoo
01-07-2025
- Health
- Yahoo
InterShunt initiates study of device for heart failure treatment
InterShunt Technologies has initiated the EASE HF2 early feasibility study to assess the InterShunt percutaneous atrial shunt catheter (PAS-C) system, intended to alleviate symptoms of heart failure and enhance the quality of life for patients. The first procedure in the US using the device was performed at The Christ Hospital Health Network in Cincinnati, Ohio, by Dr Sitaramesh Emani and the Structural Heart Intervention Team. With plans to enrol 20 subjects across up to six US cities, the study targets individuals with heart failure with reduced ejection fraction (HFrEF), which is a condition characterised by the heart's inability to pump effectively. The PAS-C device aims to generate an opening between the upper chambers of the heart. It leverages a mechanical cutting technique that does not cause scarring and helps in the natural heart movement. By reducing the pressure in the left atrium, the solution has the potential to alleviate symptoms. It also safely removes a specific piece of tissue from the interatrial septum. This process establishes a shunt from the left to the right atrium, which helps to relieve the elevated pressure in the left atrium, thus minimising heart failure symptoms. InterShunt Technologies CEO Harlee Sorkin said: "This first enrolment is a big step for our team and for people living with heart failure. We are incredibly thankful to the patient, their family, and the team at The Christ Hospital for making this possible. "Because the procedure leaves nothing behind in the heart, it avoids the risks of permanent implants and keeps future treatment options open." Heart failure is a major cause of hospitalisation for adults above 65 years old and is responsible for a significant portion of Medicare expenditure. "InterShunt initiates study of device for heart failure treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Forbes
06-06-2025
- Health
- Forbes
How AI Is Helping Cancer Patients: Saving Lives And Money
Medical technology concept. Medical doctor. getty Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times the cost of treatment for other common health conditions, according to AARP. The American Cancer Society projected that In 2025, more than 2 million people in the U.S. are expected to be diagnosed with cancer, with over 618,000 deaths projected. With these high costs, artificial intelligence (AI) is offering new solutions that are not only saving lives but also making cancer care more affordable. Early detection is one of the most effective ways to reduce cancer treatment costs. When cancer is caught in its earliest stages, treatments tend to be less aggressive and more affordable. At The Christ Hospital, AI has significantly improved lung cancer detection. 'Nearly 70% of lung cancer cases are now found at stage I or II, well above the national average of 46%,' said Seth Howard, executive vice president of research and development at Epic. 'In just six months, over 60 patients started treatment earlier, significantly improving their chances of survival.' By diagnosing cancer earlier, AI allows doctors to offer more cost-effective treatment options, which helps lower the financial burden on both patients and healthcare systems. ArteraAI is another example of how AI is transforming cancer care. Their AI technology is helping doctors determine which cancer treatments are best for their patients, preventing unnecessary therapies. 'AI is the most transformative tech we've had in a long time,' said Andre, founder of Artera. 'The impact AI has had on the healthcare system is as powerful as computers have had on the healthcare system. With the ArteraAI Prostate Test, we can personalize treatments, reducing unnecessary costs while improving outcomes.' The ArteraAI Prostate Test is fully reimbursed by Medicare under its established payment rate, meaning no out-of-pocket costs for eligible Medicare patients. This makes prostate cancer care more affordable and reduces financial strain during treatment. Surgery is often a key part of cancer treatment. Proprio, a company that has developed AI-powered surgical technology, provides surgeons with real-time data during operations, reducing the need for traditional imaging like CT scans and X-rays. This technology allows for faster surgeries, less strain on hospital staff, and quicker recovery times, which ultimately lowers the cost of care for patients. Another breakthrough demonstrating AI's transformative potential in cancer care is AION Biosystems' TempShield device. A recent study showed that TempShield, an AI-powered wearable thermometer for oncology patients, can reduce mortality rates by an astonishing 90% among cancer patients undergoing chemotherapy and inpatient hospital stays by 79%. This innovation addresses a crucial, yet often overlooked, fact: more than 50% of cancer deaths are preventable because they result from infections like pneumonia rather than cancer itself. If you spot a temperature spike (and hence an infection) early and treat it, you save lives. TempShield's continuous temperature monitoring provides clinicians with alerts up to 72 hours before symptoms of infection appear, enabling earlier intervention. 'The real danger in cancer care isn't just the disease—it's the complications we miss,' said Sam Barend, CEO of AION Biosystems. 'TempShield is a game-changer: small, simple, and affordable, and it's helping save lives by catching infections before symptoms appear—just like the blood glucose monitor did for diabetes.' AI is revolutionizing cancer care, not only improving outcomes but also making treatment more affordable. Early detection, personalized treatment, and more efficient surgeries all contribute to lowering the financial burden on patients while providing better care. With innovations like the ArteraAI Prostate Test and TempShield, AI is making cancer care smarter, more accessible, and more cost-effective for patients across the globe. As AI technologies continue to evolve, they will undoubtedly play an even greater role in both saving lives and reducing the financial strain of cancer treatment.
